Development of Drugs That Target Prostate Cancer
开发针对前列腺癌的药物
基本信息
- 批准号:7291848
- 负责人:
- 金额:--
- 依托单位:
- 依托单位国家:美国
- 项目类别:
- 财政年份:
- 资助国家:美国
- 起止时间:至
- 项目状态:未结题
- 来源:
- 关键词:
项目摘要
We are attempting to develop novel agents that alter the biology of the cancer. In order to accomplish this goal, we have initiated a collaboration with a unique computational chemistry company to design compounds that abrogate key molecular targets in the development, progression and metastasis of cancer. These studies are just being initiated but could provide valuable new agents.A successful drug development program requires a complete understanding of the clinical pharmacology of the agent(s) being evaluated. One of our interests is to utilize pharmacokinetic/pharmacodynamic concepts in the development of novel anticancer agents. This has led to attempts to optimize therapy through characterizing the pharmacogenetics of patients and appreciates for potential drug interactions. Agents that we have recently been involved with include: MS275, UCN01, perifosine, OSI774, depsipeptide, 17-DMAG, COL3, flavopiridol, phenylbutyrate, PSC833 and phenylacetate.We have found that ketoconazole exerts a cystostatic effect on panel of human prostate cancer cell lines, with IC50 values of 5 ug/mL, 12 ug/mL and 25 ug/mL for LNCaP, PC3/PC3M, and DU145 cells, respectively. This resistance was associated with a lesser degree of Raf-1 and Bcl-2 phosphorylation. Combinations of microtubule-active drugs with ketoconazole were beneficial in DU145 cancer cells. Furthermore, ketoconazole blocked the recovery of all the prostate cancer cell lines following 24 h-pulse treatment.To build on the preclinical observations above, we initiated a Phase I trial of ketoconazole plus weekly docetaxel in patients with AIPC. The primary objective of this study is to determine the side effect profile and determine the MTD. In recognition oof possible drug-drug interations, starting doses of 5 mg/m2 and 1200 mg/d were used for docetaxel and ketoconazole, respectively. Significant hepatotoxicity was noted with a docetaxel dose of 10 mg/m2. We have therefore modified the dosing regimen to 600 mg/d of ketoconazole and 10 mg/m2 of docetaxel. A total of 22 patients have been treated with this combination to date and pharmacokinetic analyses are currently ongoing.
我们正试图开发新的药物来改变癌症的生物学特性。为了实现这一目标,我们与一家独特的计算化学公司合作,设计出能够消除癌症发展、进展和转移中关键分子靶点的化合物。这些研究才刚刚开始,但可以提供有价值的新药物。一个成功的药物开发计划需要对正在评估的药物的临床药理学有全面的了解。我们的兴趣之一是利用药代动力学/药效学的概念在开发新的抗癌药物。这导致人们试图通过表征患者的药物遗传学来优化治疗,并了解潜在的药物相互作用。我们最近参与的代理商包括:我们发现酮康唑对一组人前列腺癌细胞系具有膀胱抑制作用,对LNCaP、PC 3/PC 3 M、PC 3/PC 3 M、PC 3/PC 3 M和PC 3/PC 3 M的IC 50值分别为5 μ g/mL、12 μ g/mL和25 μ g/mL,和DU 145细胞。这种抗性与Raf-1和Bcl-2磷酸化程度较低有关。微管活性药物与酮康唑的组合在DU 145癌细胞中是有益的。此外,酮康唑阻断了所有的前列腺癌细胞系的恢复后,24小时脉冲treatment.To建立在上述临床前观察,我们启动了一项I期临床试验,酮康唑加每周多西他赛与AIPC患者。本研究的主要目的是确定副作用特征并确定MTD。考虑到可能的药物相互作用,多西他赛和酮康唑的起始剂量分别为5 mg/m2和1200 mg/d。多西他赛剂量为10 mg/m2时观察到显著肝毒性。因此,我们将给药方案修改为600 mg/d酮康唑和10 mg/m2多西他赛。迄今为止,共有22例患者接受了该联合治疗,目前正在进行药代动力学分析。
项目成果
期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
数据更新时间:{{ journalArticles.updateTime }}
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
数据更新时间:{{ journalArticles.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ monograph.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ sciAawards.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ conferencePapers.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ patent.updateTime }}
William Douglas Figg其他文献
Systemic Treatment with the Janus Kinase Inhibitor Baricitinib in Ocular Chronic Graft-versus-Host Disease
- DOI:
10.1016/j.xops.2024.100627 - 发表时间:
2025-01-01 - 期刊:
- 影响因子:
- 作者:
Taylor McManus;Noa G. Holtzman;Aaron Zhao;Chantal Cousineau-Krieger;Susan Vitale;Edmond J. FitzGibbon;Debbie Payne;Janine Newgen;Celestina Igbinosun;Annie P. Im;Cody Peer;William Douglas Figg;Edward W. Cowen;Jacqueline W. Mays;Steven Pavletic;M.Teresa Magone - 通讯作者:
M.Teresa Magone
William Douglas Figg的其他文献
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
{{ truncateString('William Douglas Figg', 18)}}的其他基金
Analytical Method Develop.--Anticancer /Antiviral Agents
分析方法开发--抗癌/抗病毒药物
- 批准号:
6558335 - 财政年份:
- 资助金额:
-- - 项目类别:
Development of Pharmacokinetic Models to Characterize the Disposition of New Ant
开发表征新蚂蚁处置的药代动力学模型
- 批准号:
6433351 - 财政年份:
- 资助金额:
-- - 项目类别:
Identify SNPs and Polymorphisms that are Important in th
识别重要的 SNP 和多态性
- 批准号:
7055447 - 财政年份:
- 资助金额:
-- - 项目类别:
Using Clinical Pharmacology Principles to Develop New Anticancer Therapies
利用临床药理学原理开发新的抗癌疗法
- 批准号:
10487279 - 财政年份:
- 资助金额:
-- - 项目类别:
Identify SNPs and Polymorphisms Involved in the Development of Prostate Cancer
鉴定参与前列腺癌发展的 SNP 和多态性
- 批准号:
8937742 - 财政年份:
- 资助金额:
-- - 项目类别:
相似海外基金
Development of novel drugs against an untreated common target in multiple cancers
针对多种癌症中未经治疗的共同靶标开发新药
- 批准号:
10001247 - 财政年份:2021
- 资助金额:
-- - 项目类别:
Feasibility Studies
Development of Drugs to Target Arginine Biosythesis in Mycobacterium tuberculosis
结核分枝杆菌精氨酸生物合成靶向药物的开发
- 批准号:
10396608 - 财政年份:2021
- 资助金额:
-- - 项目类别:
Development of Drugs to Target Arginine Biosythesis in Mycobacterium tuberculosis
结核分枝杆菌精氨酸生物合成靶向药物的开发
- 批准号:
10171201 - 财政年份:2021
- 资助金额:
-- - 项目类别:
Development of Drugs to Target Arginine Biosythesis in Mycobacterium tuberculosis
结核分枝杆菌精氨酸生物合成靶向药物的开发
- 批准号:
10589861 - 财政年份:2021
- 资助金额:
-- - 项目类别:
Development of smart drugs for the sensing and inhibition of target biomolecules
开发用于传感和抑制目标生物分子的智能药物
- 批准号:
21K19317 - 财政年份:2021
- 资助金额:
-- - 项目类别:
Grant-in-Aid for Challenging Research (Exploratory)
Development of target-selective mid-size drugs using cyclic peptide derivatives
利用环肽衍生物开发靶点选择性中型药物
- 批准号:
20H03362 - 财政年份:2020
- 资助金额:
-- - 项目类别:
Grant-in-Aid for Scientific Research (B)
Development of the treatment strategy for molecular target anticancer drugs to avoid serious side effects
制定分子靶向抗癌药物治疗策略以避免严重副作用
- 批准号:
20K07150 - 财政年份:2020
- 资助金额:
-- - 项目类别:
Grant-in-Aid for Scientific Research (C)
Applied clinical study for development of rapid plasma concentration measurement method of molecular target anti-cancer drugs
分子靶向抗癌药物血药浓度快速测定方法开发的应用临床研究
- 批准号:
19K16442 - 财政年份:2019
- 资助金额:
-- - 项目类别:
Grant-in-Aid for Early-Career Scientists
Development of covalent drugs activatable by the target enzymes
开发可被靶酶激活的共价药物
- 批准号:
18K14356 - 财政年份:2018
- 资助金额:
-- - 项目类别:
Grant-in-Aid for Early-Career Scientists
Elucidation of occurrence mechanism of common complications of various EGFR molecular target drugs and development of therapeutic drug for alleviation.
阐明各种EGFR分子靶向药物常见并发症的发生机制并开发缓解治疗药物。
- 批准号:
18K17191 - 财政年份:2018
- 资助金额:
-- - 项目类别:
Grant-in-Aid for Early-Career Scientists